STRATA Skin Sciences, Inc. (SSKN): Nasdaq/NYSE listing notice — Strata Skin Sciences gets 180-day Nasdaq extension to June 24, 2024 for bid price rule

STRATA Skin Sciences, Inc.

Nasdaq granted 180-day extension until June 24, 2024 to regain $1.00 minimum bid compliance.
Company had been noncompliant since June 29, 2023; initial cure period ended Dec 26, 2023.
To regain compliance, closing bid must be at least $1.00 for 10 consecutive business days.
Company may consider a reverse stock split to cure the deficiency if needed.
No immediate effect on listing or trading; stock continues on Nasdaq under symbol 'SSKN'.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

STRATA Skin Sciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 27, 2023, the Company received further notification from NASDAQ that the Company had been granted a 180 day extension to June 24, 2024 to regain compliance with the minimum bid price requirement. The Company will regain compliance if the closing bid price of its common stock is $1.00 per share or higher for a minimum period of ten consecutive business days during this compliance period, as confirmed by written notification from NASDAQ. If the Company does not achieve compliance by June 24, 2024, the Company may file an appeal to Nasdaq’s Hearing Panel with a plan to resolve the bid

View on SEC.gov

Browse all listing & compliance notices →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-000342

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.